NVO Novo Nordisk

   By Maria Armental 
 

Danish drug maker Novo Nordisk A/S's (NVO) injectable diabetes drug has been approved in the U.S. to fight obesity, the Food and Drug Administration said Tuesday.

Liraglitude, which is sold as Victoza for diabetes and will be marketed as Saxenda to fight obesity, is the first once-daily such treatment, the FDA said.

Trial data submitted to the FDA showed that across all trials, 60% of patients achieved a 5% weight loss and 31% achieved a 10% weight loss.

The company said the drug's price hasn't been determined.

-Tess Stynes contributed to this article.

Write to Maria Armental at maria.armental@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires